This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
In vivo impact of JAK3 A573V mutation revealed using zebrafish
Cellular and Molecular Life Sciences Open Access 27 May 2022
-
The JAK/STAT signaling pathway: from bench to clinic
Signal Transduction and Targeted Therapy Open Access 26 November 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Speck NA, Gilliland DG . Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002; 2: 502–513.
Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148–152.
Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103: 2480–2489.
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10: 65–75.
Suzuki M, Abe A, Kiyoi H, Murata M, Ito Y, Shimada K et al. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation. Leukemia 2006; 20: 1168–1169.
Hirose Y, Kudo K, Kiyoi H, Hayashi Y, Naoe T, Kojima S . Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome. Leukemia 2003; 17: 2250–2252.
O'Shea JJ, Husa M, Li D, Hofmann SR, Watford W, Roberts JL et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 2004; 41: 727–737.
Villeval JL, James C, Pisani DF, Casadevall N, Vainchenker W . New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Semin Thromb Hemost 2006; 32: 341–351.
Acknowledgements
We thank Ms Manami Kira for secretarial assistance. This work was supported by Grants-in-Aid from the National Institute of Biomedical Innovation, the Ministry of Health, Labor and Welfare and the Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kiyoi, H., Yamaji, S., Kojima, S. et al. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 21, 574–576 (2007). https://doi.org/10.1038/sj.leu.2404527
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404527
This article is cited by
-
In vivo impact of JAK3 A573V mutation revealed using zebrafish
Cellular and Molecular Life Sciences (2022)
-
The JAK/STAT signaling pathway: from bench to clinic
Signal Transduction and Targeted Therapy (2021)
-
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
Leukemia (2021)
-
Are peptides a solution for the treatment of hyperactivated JAK3 pathways?
Inflammopharmacology (2019)
-
The aurora kinases in cell cycle and leukemia
Oncogene (2015)